Where Cytokinetics Stands With Analysts
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish and somewhat bullish ratings for Cytokinetics (NASDAQ:CYTK) in the last quarter, with no bearish or indifferent ratings. The average price target is $56.43, implying an upside from the current price of $32.96. However, this average has decreased by 5.95% from the previous average price target of $60.00.
August 22, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts are bullish on Cytokinetics, with an average price target of $56.43, indicating potential upside from the current price.
The bullish ratings from analysts indicate a positive outlook for Cytokinetics. The average price target is significantly higher than the current price, suggesting potential upside. However, the decrease in the average price target could indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100